Modern Healthcare News
 
RSS feed

Pharmaceuticals news and information

Information
Send nominations for Excellence in Governance Award
Modern Healthcare | October 18, 2014
Modern Healthcare is now accepting nominations for its inaugural Excellence in Governance awards for 2015.
FULL STORY »
 

Information
Canadian Ebola vaccine to begin testing
Associated Press | October 13, 2014
An experimental Canadian-made Ebola vaccine that has shown promise in tests on primates is beginning clinical trials on humans in the U.S.
FULL STORY »
 

Information
Petri-dish form of Alzheimer's aids drug testing
Boston Globe | October 13, 2014
For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer's in a Dish: a petri dish with human brain cells that develop the telltale structures of Alzheimer's disease. In doing so, they resolved a long-standing problem of how to study...
FULL STORY »
 

Magazine
Data Points for Oct. 13, 2014
Modern Healthcare | October 11, 2014 | Print Magazine Print Magazine Subscription Details
Data Points for the week of Oct. 13, 2014, covered the following topics: cancer, mental health, antimicrobial drugs, medical costs for vehicle crash victims, healthcare expenditures and Ebola.
FULL STORY »
 

Magazine
340B drug programs serving wealthier communities: study
By Jaimy Lee and Adam Rubenfire | October 11, 2014 | Print Magazine Print Magazine Subscription Details
Healthcare organizations that joined the federal 340B drug discount program after 2004 were more likely than other program participants to serve wealthier communities with higher rates of health insurance, according to a study.
FULL STORY »
 


Advertisement | View Media Kit

Magazine
New hepatitis C drug costs nearly $100,000
By Paul Demko | October 11, 2014 | Print Magazine Print Magazine Subscription Details
A second potential blockbuster drug from Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, it is certain to spark further debate over the pricing of specialty drugs.
FULL STORY »
 

News
Gilead Sciences gets go-ahead for Harvoni, its second high-priced hepatitis C drug
Paul Demko | October 10, 2014 | Basic Web Basic Web Subscription Details
A second potential blockbuster drug manufactured by Gilead Sciences to treat hepatitis C has been approved by the FDA. But at a cost of nearly $100,000 for a full course of treatment, the drug is certain to spark further debate over the pricing of specialty drugs
FULL STORY »
 

News
PhRMA again challenges 340B rule on orphan-drug discounts
By Adam Rubenfire | October 10, 2014 | Basic Web Basic Web Subscription Details
The pharmaceutical industry has gone back to court to block a rule that allows safety net hospitals to buy so-called orphan drugs at a discount through the 340B program to treat non-orphan conditions or diseases.
FULL STORY »
 

News
Reform Update: Generic drugs' high prices spur fears of failed drug adherence
By Virgil Dickson | October 09, 2014 | Basic Web Basic Web Subscription Details
Faced with the rising costs of generic prescription drugs, health insurers increasingly are turning to tiers and preferred lists on their formularies to keep costs down. Those strategies previously were used only for brand-name and specialty drugs.
FULL STORY »
 

Information
Researchers aren't ruling out treatment used in Dallas case
Wall Street Journal | October 09, 2014
The Ebola patient in Dallas who received an experimental Chimerix drug died Wednesday, but infectious-disease researchers keen for any new tool to fight the widening viral outbreak said it was premature to rule out the drug’s potential to treat Ebola.
FULL STORY »
 

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.